General selection criteria of patients for radioembolization of liver tumors: An international working group report

Douglas Coldwell, Bruno Sangro, Harpreet Wasan, Riad Salem, Andrew Kennedy*

*Corresponding author for this work

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

A combined treatment approach that incorporates surgical resection, ablation, chemotherapy, targeted agents, and radiotherapy has augmented the management of liver tumors (both primary and metastatic). The challenge that remains is how to reduce the burden of liver disease and thus enable greater patient eligibility for resection as well as lengthened survival for those who remain unsuitable for surgery. Radioembolization can deliver high doses of radiation preferentially to liver tumors and is a valuable treatment option that should be considered as part of a multimodal treatment approach for the management of patients in whom the liver is the sole or dominant site of disease. Essential in this consideration is a careful assessment by a multidisciplinary team of the individuals most likely to benefit from this treatment modality. Along with the clinical benefits, integration of radioembolization into the treatment paradigm can provide added options of using systemic chemotherapy synergistically as a radiosensitizer and to control extrahepatic metastases, permitting a reduction in hepatic disease and conserving remaining liver function. If successful, the possibility of improved patient survival and quality of life is increased.

Original languageEnglish (US)
Pages (from-to)337-341
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Patient Selection
Liver
Neoplasms
Drug Therapy
Combined Modality Therapy
Survival
Therapeutics
Liver Diseases
Radiotherapy
Quality of Life
Radiation
Neoplasm Metastasis

Keywords

  • eligibility
  • hepatic
  • liver
  • selection
  • yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{8217e4790ea94baca36c1a7d44af2534,
title = "General selection criteria of patients for radioembolization of liver tumors: An international working group report",
abstract = "A combined treatment approach that incorporates surgical resection, ablation, chemotherapy, targeted agents, and radiotherapy has augmented the management of liver tumors (both primary and metastatic). The challenge that remains is how to reduce the burden of liver disease and thus enable greater patient eligibility for resection as well as lengthened survival for those who remain unsuitable for surgery. Radioembolization can deliver high doses of radiation preferentially to liver tumors and is a valuable treatment option that should be considered as part of a multimodal treatment approach for the management of patients in whom the liver is the sole or dominant site of disease. Essential in this consideration is a careful assessment by a multidisciplinary team of the individuals most likely to benefit from this treatment modality. Along with the clinical benefits, integration of radioembolization into the treatment paradigm can provide added options of using systemic chemotherapy synergistically as a radiosensitizer and to control extrahepatic metastases, permitting a reduction in hepatic disease and conserving remaining liver function. If successful, the possibility of improved patient survival and quality of life is increased.",
keywords = "eligibility, hepatic, liver, selection, yttrium-90",
author = "Douglas Coldwell and Bruno Sangro and Harpreet Wasan and Riad Salem and Andrew Kennedy",
year = "2011",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e3181ec61bb",
language = "English (US)",
volume = "34",
pages = "337--341",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

General selection criteria of patients for radioembolization of liver tumors : An international working group report. / Coldwell, Douglas; Sangro, Bruno; Wasan, Harpreet; Salem, Riad; Kennedy, Andrew.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 3, 01.06.2011, p. 337-341.

Research output: Contribution to journalReview article

TY - JOUR

T1 - General selection criteria of patients for radioembolization of liver tumors

T2 - An international working group report

AU - Coldwell, Douglas

AU - Sangro, Bruno

AU - Wasan, Harpreet

AU - Salem, Riad

AU - Kennedy, Andrew

PY - 2011/6/1

Y1 - 2011/6/1

N2 - A combined treatment approach that incorporates surgical resection, ablation, chemotherapy, targeted agents, and radiotherapy has augmented the management of liver tumors (both primary and metastatic). The challenge that remains is how to reduce the burden of liver disease and thus enable greater patient eligibility for resection as well as lengthened survival for those who remain unsuitable for surgery. Radioembolization can deliver high doses of radiation preferentially to liver tumors and is a valuable treatment option that should be considered as part of a multimodal treatment approach for the management of patients in whom the liver is the sole or dominant site of disease. Essential in this consideration is a careful assessment by a multidisciplinary team of the individuals most likely to benefit from this treatment modality. Along with the clinical benefits, integration of radioembolization into the treatment paradigm can provide added options of using systemic chemotherapy synergistically as a radiosensitizer and to control extrahepatic metastases, permitting a reduction in hepatic disease and conserving remaining liver function. If successful, the possibility of improved patient survival and quality of life is increased.

AB - A combined treatment approach that incorporates surgical resection, ablation, chemotherapy, targeted agents, and radiotherapy has augmented the management of liver tumors (both primary and metastatic). The challenge that remains is how to reduce the burden of liver disease and thus enable greater patient eligibility for resection as well as lengthened survival for those who remain unsuitable for surgery. Radioembolization can deliver high doses of radiation preferentially to liver tumors and is a valuable treatment option that should be considered as part of a multimodal treatment approach for the management of patients in whom the liver is the sole or dominant site of disease. Essential in this consideration is a careful assessment by a multidisciplinary team of the individuals most likely to benefit from this treatment modality. Along with the clinical benefits, integration of radioembolization into the treatment paradigm can provide added options of using systemic chemotherapy synergistically as a radiosensitizer and to control extrahepatic metastases, permitting a reduction in hepatic disease and conserving remaining liver function. If successful, the possibility of improved patient survival and quality of life is increased.

KW - eligibility

KW - hepatic

KW - liver

KW - selection

KW - yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=79958268563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958268563&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181ec61bb

DO - 10.1097/COC.0b013e3181ec61bb

M3 - Review article

C2 - 20921882

AN - SCOPUS:79958268563

VL - 34

SP - 337

EP - 341

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -